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Abstract Ageing research and more generally the study of
the functional basis of human diseases profit enormously
from the large-scale approaches and resources in mouse
functional genomics: systematic targeted mutation of the
mouse genome, systemic phenotyping in mouse clinics,
and the archiving and distribution of the mouse resources
in public repositories. INFRAFRONTIER, the European
research infrastructure for the development, systemic
phenotyping, archiving and distribution of mammalian
models, offers access to sustainable mouse resources for
biomedical research. INFRAFRONTIER promotes the
global sharing of high-quality resources and data and thus
contributes to data reproducibility and animal welfare.
INFRAFRONTIER puts great effort into international
standardisation and quality control and into technology
development to improve and expand experimental proto-
cols, reduce the use of animals in research and increase the
reproducibility of results. In concert with the research
community and the International Mouse Phenotyping
Consortium (IMPC), INFRAFRONTIER is currently
developing new pilot platforms and services for the
research on ageing and age-related diseases.
Comprehensive analysis of ageing phenotypes
in a mouse clinic
Neff et al. (2013) recently reported on a large-scale study
to test whether the extended lifespans of mice treated with
the drug rapamycin (Harrison et al. 2009; Miller et al.
2011) can be attributed to direct rapamycin effects on
ageing. They used the unique setup of the German Mouse
Clinic (www.mouseclinic.de), which allows to compre-
hensively study the effects of genotypes, environmental
factors or treatments on phenotypes (Fuchs et al. 2012;
Gailus-Durner et al. 2005, 2009), to carry out a compre-
hensive analysis of rapamycin effects on more than 150
ageing phenotypes across 25 different tissues in male
C57BL/6 J mice. The study, which was carried out in
cooperation with the German Center for Neurological
Diseases (DZNE), analysed three cohorts of mice on
rapamycin supplemented diets starting in early adulthood
(4 months), midlife (13 months) and late in life
(20–22 months). Each cohort was treated for at least
12 months before a comprehensive phenotypic analysis
was performed (starting at 16, 25 and 34 months of age,
respectively). Those ageing phenotypes rescued by rapa-
mycin were further assessed in groups of young adult mice
to identify ageing-independent rapamycin effects.
As in previous studies, Neff et al. (2013) observed that
rapamycin extended lifespan in the treated mice. There
was, however, no systematic effect of the drug on ageing
phenotypes, since only a subset of traits was rescued by
rapamycin. Moreover, many of those traits were equally
affected by rapamycin in young mice, suggesting ageing-
independent drug effects. The authors therefore conclude
that the effects of rapamycin on longevity are not neces-
sarily mediated by direct effects on ageing traits but could
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rather be the results of a reduction of life-limiting
pathologies such as specific cancers by rapamycin.
The study byNeff and colleagues exemplifies the strength
of the mouse clinic concept, which allows obtaining a truly
systemic understanding of how disease phenotypes are
affected by the genetic make-up, lifestyle or treatment
regime (or a combination of those). Researchers whowant to
test their hypothesis on how ageing is affected by specific
treatments or challenges can plan, design and initiate the
experiments in their own facilities, where the setup of the
cohorts, breeding and ageing can be done. The comprehen-
sive phenotypic analysis is then carried out by the mouse
clinic, and researchers profit from the extensive expert
knowledge, sophisticated high-end technology and tailor-
made statistical analysis offered by these large-scale phe-
notyping facilities. European mouse clinics offering a stan-
dardised first-line phenotyping screen are located in
Germany (GermanMouse Clinic, Munich), France (Institute
Clinique de la Souris, Strasbourg) and the United Kingdom
(Mary-Lyon Centre, Harwell and Wellcome Trust Sanger
Institute, Hinxton). A novel mouse clinic is currently
becoming operative in the Czech Republic (CzechCentre for
Phenogenomics, Prague). All these European mouse clinics
are organised in the INFRAFRONTIER network (www.
infrafrontier.eu, see below). Modelled on these successful
examples, mouse clinics meanwhile also operate in North
America, Asia and Australia.
European large-scale functional genomics
initiatives and the INFRAFRONTIER research
infrastructure
Mouse studies like the one of Neff and colleagues help dis-
cover the functional basis of ageing-related diseases and
other human disease conditions (Fuchs et al. 2011; Schughart
et al. 2012; Vandamme 2015) and are also important in
preclinical screening (Varga et al. 2010) and drug develop-
ment (Neschen et al. 2015; Sharpless and Depinho 2006;
Zambrowicz and Sands 2003). As exemplified by the mouse
clinic concept, Europe has played a leading role, both in the
initiation of large-scale approaches for functional mouse
genomics and in the continuous cross-laboratory standardi-
sation of operation procedures and quality measures that
allowed them to evolve into truly global scientific enterprises
(Beckers et al. 2009; Rosenthal and Brown 2007).
Using a combination of gene trapping and gene targeting
the European Conditional Mouse Mutagenesis Program
(EUCOMM) as part of the International Knock-Out Mouse
Consortium (IKMC) created a resource of mutated ES cells
and mice for each protein-coding gene in the mammalian
genome (Collins et al. 2007; Friedel et al. 2007). Drawing
on this resource, a consortium of European mouse clinics
participating in the EUMODIC initiative (European Mouse
Disease Clinic) showed that it is feasible and also scalable
to carry out a multi-laboratory programme for the broad-
based phenotypic analysis of mammalian gene function
(Angelis et al. 2015; Morgan et al. 2010). The success of
this programme led to the initiation of the International
Mouse Phenotyping Consortium (IMPC, www.mousephe
notype.org), which brought large-scale phenotyping to the
global level, with the aim to create an openly accessible
catalogue of mammalian gene function (Brown and Moore
2012; Koscielny et al. 2014).
At the same time as the large-scale approaches for the
mutagenesis and systemic phenotyping of mice were
developed, a consortium of European research centres
started to build the European Mouse Mutant Archive
(EMMA), a repository that archives and distributes mutant
mouse lines submitted by individual researchers and gen-
erated by the large-scale initiatives IKMC and IMPC
(Hagn et al. 2007). Starting in 2001, the EMMA repository
has been continually growing (Fig. 1a) and currently is the
third largest repository for mouse strains listed on the In-
ternational Mouse Strain Resource (www.findmice.org/
repository) (Eppig et al. 2015), distributing mouse strains
to biomedical researchers around the globe (Fig. 1b).
Building sufficient capacities and securing sustainable
access to high-quality resources for mouse functional
genomics across national borders is a challenge that
requires novel funding and governance models (Mishra
et al. 2016). In Europe, therefore, a consortium of 23
research centres across 15 countries established the pan-
European INFRAFRONTIER Research Infrastructure for
the generation, systemic phenotyping, archiving and dis-
tribution of mouse disease models. The INFRAFRONTIER
partners are mouse clinics and EMMA archiving and dis-
tribution centres. They offer an integrated portfolio of
resources and services that can be accessed via a central
web portal (www.infrafrontier.eu, Meehan et al. 2015)
(Fig. 2). In 2015, more than 1300 user projects were han-
dled by the INFRAFRONTIER Research Infrastructure.
The strategic importance of having available a sustain-
able resource for functional mouse genomics in Europe
was underlined by the inclusion of INFRAFRONTIER on
the first Roadmap of the European Strategy Forum on
Research Infrastructures (ESFRI) issued in 2006 (www.
esfri.eu). This document lists those pan-European research
infrastructures that are crucial for building the European
research area (ERA) and keeping a competitive edge to
European science. According to the ESFRI definition,
research infrastructures ‘‘are facilities, resources or ser-
vices of a unique nature that have been identified by
European research communities to conduct top-level
activities in all fields. This…covers major equipment or
sets of instruments, in addition to knowledge-containing
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resources such as collections, archives and data banks’’.
ESFRI also recognised that a sustainable pan-European
organisation and governance is required to efficiently
manage capacities and access to resources and services,
particularly if the research infrastructure is distributed
across several European countries. Therefore, in 2013 the
INFRAFRONTIER GmbH was established to act as the
central management unit of the INFRAFRONTIER
Research Infrastructure. Meanwhile the process has been
initiated to transform the INFRAFRONTIER GmbH into a
European Research Infrastructure Consortium (ERIC), a
legal form particularly created by the European Commis-
sion for pan-European research infrastructures like
INFRAFRONTIER. In the fourth iteration of the ESFRI
Fig. 1 a The European Mouse Mutant Archive (EMMA) as part of
the INFRAFRONTIER Research Infrastructure is worldwide the third
largest public repository of mutant mouse strains, with more than
5000 strains available. b The number of yearly requests for mouse
strains in the EMMA repository is continuously growing. Almost half
of the requests come from outside Europe. Mouse lines deposited by
the large-scale initiatives IKMC/IPMC are in high demand and
constituted approximately 50 % of all requests in 2015. Asterisk
Including requests from Oceania and Australia
Fig. 2 The resources and
services of the
INFRAFRONTIER Research
Infrastructure can be accessed at
the central web portal. They are
provided by the European
INFRAFRONTIER partners and
centrally coordinated by the
INFRAFRONTIER GmbH/
ERIC (see text for further
explanations)
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Roadmap which has been recently published, the
INFRAFRONTIER Research Infrastructure is highlighted
as one of the ‘Landmark Projects’.
INFRAFRONTIER helps improve animal welfare
and data reproducibility
Biomedical research infrastructures like INFRAFRONTIER
play a key role in preserving and sharing resources and
data created by publicly funded research (Mishra et al.
2016). By offering open access to centralised high-quality
resources, they help prevent duplication of efforts and
wasting of public resources. By setting standard operation
procedures and strict quality control measures, they help
reduce the irreproducibility of scientific results in preclin-
ical research, the costs of which have been recently esti-
mated to be 28 billion $ per year in the US alone
(Freedman et al. 2015).
In the case of the INFRAFRONTIER Research Infras-
tructure, this has direct implications on animal welfare and
on the validity of scientific results based on studies in mice,
which often suffer from poorly applied scientific stan-
dards (Perrin 2014; Justice and Dhillon 2016). The
INFRAFRONTIER partners are strongly committed to the
implementation of the 3R’s principle (replacement, reduc-
tion, refinement; Sabate´ 2015) and do endorse the ARRIVE
(Animal Research: Reporting of In Vivo Experiments)
Guidelines which are promoted by the National Centre for
Replacement, Refinement & Reduction of animals in
Research (www.nc3rs.org.uk/ARRIVE). Applying and
reporting strict scientific quality standards is even more
important with the spread of novel gene editing technologies
like CRISPR/Cas9. Gene editing may make mouse mutant
generation more generally accessible, but experience in
mouse genetics is required to take into account the effects of
genetic background, additional mutations and husbandry
conditions such as housing, diet or the gut microbiome
(Ericsson et al. 2015; Lloyd et al. 2015). Moreover, geno-
types may get lost due to breeding errors or fatal diseases in
the mouse colony. More than once experimental results
could not be reproduced because the genotype could not be
maintained. Public repositories such as INFRAFRONTIER/
EMMAhave both the experience and the qualitymeasures in
place to safeguard scientifically valuable mouse strains.
The INFRAFRONTIER Research Infrastructure and its
international partners put a lot of effort into the develop-
ment of new technologies that help reduce animal numbers
and refine existing animal experiments. Improving quality
control by means of blastocyst genotyping reduces the
number of animals required for cryopreservation, as well as
processing time, technical requirements and costs (Scavizzi
et al. 2015). Moreover, the methods described can also be
applied to optimise experimental design when using
CRISPR/Cas9 technologies in mouse model generation.
Improving in vitro fertilisation technology and using
refined cryoprotective agents is another way to reduce
animal numbers and overall costs (Guan et al. 2014).
INFRAFRONTIER technology development also focuses
on the improvement of transportation procedures of mouse
sperm and embryos (Kenyon et al. 2014). Coupled with
training activities to enable INFRAFRONTIER users to
work with frozen material, these activities have helped to
markedly reduce the need for shipping live animals from
the EMMA repository.
Overall, the INFRAFRONTIER Research Infrastructure
has established a successful model ‘‘for sharing animal
models, protocols and genetic information, as well as a
wealth of cross-referenced data’’, and promotes trans-
parency in animal research, as has been recently recognised
by McGrath et al. (2015).
Perspectives for ageing research
Ageing research addresses a major societal challenge. As
life expectancy increases globally, also the related health
care costs for age-related diseases surge. Publicly funded
research infrastructures have a public service mission to
address these challenges. The INFRAFRONTIER Research
Infrastructure does this in several ways: On the strategic
level, INFRAFRONTIER engages with European pro-
grammes addressing ageing and age-related diseases, such
as the joint programming initiatives ‘‘More Years, Better
Lives’’ or the ‘‘EU Joint Programme—Neurodegenerative
Disease Research (JPND)’’. On the scientific level,
INFRAFRONTIER currently interfaces with the European
ageing community to develop pilot platforms and services
for ageing research that can be offered at the European
level. These activities are tightly integrated with the current
efforts of the International Mouse Phenotyping Consor-
tium to set up a standardised ageing pipeline. The
INFRAFRONTIER Research Infrastructure, in concert
with the global large-scale resources for mouse functional
genomics, already has a lot to offer to the biomedical
research community for ageing, and it will put a lot of
effort into expanding this even further in the coming years.
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